Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Nov;17(11):85.
doi: 10.1007/s11906-015-0596-3.

Clinical Significance of Endothelial Dysfunction in Essential Hypertension

Affiliations
Review

Clinical Significance of Endothelial Dysfunction in Essential Hypertension

Eugenia Gkaliagkousi et al. Curr Hypertens Rep. 2015 Nov.

Abstract

The endothelium is recognized as a major determinant of vascular physiology and pathophysiology. Over the last few decades, a plethora of studies have implicated endothelial dysfunction in the progression of atherosclerosis and the subclinical target organ damage observed in essential hypertension. However, the clinical significance of diagnosing endothelial dysfunction in patients with essential hypertension remains under investigation. Although a number of vascular and non-vascular markers of endothelial dysfunction have been proposed, there is an ongoing quest for a marker in the clinical setting that is optimal, inexpensive, and reproducible. In addition, endothelial dysfunction emerges as a promising therapeutic target of agents that are readily available in clinical practice. In this context, a better understanding of its role in essential hypertension becomes of great importance. Here, we aim to investigate the clinical significance of endothelial dysfunction in essential hypertension by accumulating novel data on (a) early diagnosis using robust markers with prognostic value in cardiovascular risk prediction, (b) the association of endothelial dysfunction with subclinical vascular organ damage, and (c) potential therapeutic targets.

Keywords: ADMA; Endothelial dysfunction; Essential hypertension; FMD; Treatment.

PubMed Disclaimer

References

    1. J Pharmacol Exp Ther. 2014 Jul;350(1):5-13 - PubMed
    1. J Am Coll Cardiol. 2002 Aug 7;40(3):505-10 - PubMed
    1. Diabetes Care. 2012 Nov;35(11):2324-30 - PubMed
    1. Arterioscler Thromb Vasc Biol. 2003 May 1;23(5):729-36 - PubMed
    1. Lancet. 1992 Nov 7;340(8828):1111-5 - PubMed

LinkOut - more resources